Literature DB >> 32930481

Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2.

Armin Welker1, Christian Kersten2, Christin Müller3, Ramakanth Madhugiri3, Collin Zimmer2, Patrick Müller2, Robert Zimmermann2, Stefan Hammerschmidt2, Hannah Maus2, John Ziebuhr3, Christoph Sotriffer1, Tanja Schirmeister2.   

Abstract

Inhibition of coronavirus (CoV)-encoded papain-like cysteine proteases (PLpro ) represents an attractive strategy to treat infections by these important human pathogens. Herein we report on structure-activity relationships (SAR) of the noncovalent active-site directed inhibitor (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl) benzamide (2 b), which is known to bind into the S3 and S4 pockets of the SARS-CoV PLpro . Moreover, we report the discovery of isoindolines as a new class of potent PLpro inhibitors. The studies also provide a deeper understanding of the binding modes of this inhibitor class. Importantly, the inhibitors were also confirmed to inhibit SARS-CoV-2 replication in cell culture suggesting that, due to the high structural similarities of the target proteases, inhibitors identified against SARS-CoV PLpro are valuable starting points for the development of new pan-coronaviral inhibitors.
© 2020 The Authors. Published by Wiley-VCH GmbH.

Entities:  

Keywords:  Antiviral agents; Computational chemistry; Drug design; Protease inhibitors; Structure-activity relationships

Year:  2020        PMID: 32930481     DOI: 10.1002/cmdc.202000548

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  9 in total

Review 1.  Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies.

Authors:  Sarah Mousavi; Shima Zare; Mahmoud Mirzaei; Awat Feizi
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-09-25       Impact factor: 2.585

2.  Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.

Authors:  Lennart Brewitz; Jos J A G Kamps; Petra Lukacik; Claire Strain-Damerell; Yilin Zhao; Anthony Tumber; Tika R Malla; Allen M Orville; Martin A Walsh; Christopher J Schofield
Journal:  ChemMedChem       Date:  2022-02-17       Impact factor: 3.540

3.  SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.

Authors:  Adam Stasiulewicz; Alicja W Maksymiuk; Mai Lan Nguyen; Barbara Bełza; Joanna I Sulkowska
Journal:  Int J Mol Sci       Date:  2021-04-12       Impact factor: 5.923

4.  Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.

Authors:  Julian Breidenbach; Carina Lemke; Thanigaimalai Pillaiyar; Laura Schäkel; Ghazl Al Hamwi; Miriam Diett; Robin Gedschold; Nina Geiger; Vittoria Lopez; Salahuddin Mirza; Vigneshwaran Namasivayam; Anke C Schiedel; Katharina Sylvester; Dominik Thimm; Christin Vielmuth; Lan Phuong Vu; Maria Zyulina; Jochen Bodem; Michael Gütschow; Christa E Müller
Journal:  Angew Chem Int Ed Engl       Date:  2021-03-24       Impact factor: 16.823

5.  Identification of bio-active food compounds as potential SARS-CoV-2 PLpro inhibitors-modulators via negative image-based screening and computational simulations.

Authors:  Shovonlal Bhowmick; Nora Abdullah AlFaris; Jozaa Zaidan ALTamimi; Zeid A ALOthman; Pritee Chunarkar Patil; Tahany Saleh Aldayel; Saikh Mohammad Wabaidur; Achintya Saha
Journal:  Comput Biol Med       Date:  2022-04-01       Impact factor: 6.698

Review 6.  Inhibitors of SARS-CoV-2 PLpro.

Authors:  Dale J Calleja; Guillaume Lessene; David Komander
Journal:  Front Chem       Date:  2022-04-26       Impact factor: 5.545

7.  Discovery of the Cryptic Sites of SARS-CoV-2 Papain-like Protease and Analysis of Its Druggability.

Authors:  Yue Qiu; Qing Liu; Gao Tu; Xiao-Jun Yao
Journal:  Int J Mol Sci       Date:  2022-09-24       Impact factor: 6.208

8.  GNPS-guided discovery of xylacremolide C and D, evaluation of their putative biosynthetic origin and bioactivity studies of xylacremolide A and B.

Authors:  Felix Schalk; Janis Fricke; Soohyun Um; Benjamin H Conlon; Hannah Maus; Nils Jäger; Thorsten Heinzel; Tanja Schirmeister; Michael Poulsen; Christine Beemelmanns
Journal:  RSC Adv       Date:  2021-05-24       Impact factor: 4.036

9.  Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates.

Authors:  Mateus S M Serafim; Jadson C Gertrudes; Débora M A Costa; Patricia R Oliveira; Vinicius G Maltarollo; Kathia M Honorio
Journal:  Biosci Rep       Date:  2021-03-26       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.